A. M. Lovering
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
A. M. Lovering has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
D. S. Reeves
Bristol Centre for Antimicrobial Research and Evaluation, Southmead Health Services NHS Trust; Univeristy of Bristol; Department of Medical Microbiology
4 shared publicationsA. P. MacGowan
Bristol Centre for Antimicrobial Research and Evaluation, Microbiology Department, Southmead Hospital, North Bristol NHS Trust, Bristol BS10 5NB, UK
3 shared publications- Alasdair P. MacGowan
Bristol Centre for Antimicrobial Research and Evaluation. University of Bristol, United Kingdom
3 shared publications L. O. White
Regional Antimicrobial Reference LaboratoryDepartment of Microbiology, Soulhmead Hospital, Westbury on Trym, Bristol BS10 5NB, UK
3 shared publications- Gordon C. Bannister
Avon Orthopaedic Centre, Southmead Hospital, Bristol, UK
2 shared publications J. Zhang
2 shared publications
Latest Publications
- Open Access
- 13 March 2003
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 51 (4) , 1041-1042
A high performance liquid chromatography (HPLC) assay for linezolid in continuous ambulatory peritoneal dialysis fluid (CAPDF)
*Corresponding author. Tel: +44-117-9595654; Fax: +44-117-9592317; E-mail: tobin_c@southmead.swest.nhs.uk
- 13 March 2003
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 51 (4) , 1041-1042
Open AccessA high performance liquid chromatography (HPLC) assay for linezolid in continuous ambulatory peritoneal dialysis fluid (CAPDF)
*Corresponding author. Tel: +44-117-9595654; Fax: +44-117-9592317; E-mail: tobin_c@southmead.swest.nhs.uk
- Open Access
- 14 January 2003
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 51 (2) , 465-467
Variation in the content of ciprofloxacin susceptibility testing discs: its effect on the BSAC disc method
- 14 January 2003
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 51 (2) , 465-467
Open AccessVariation in the content of ciprofloxacin susceptibility testing discs: its effect on the BSAC disc method
- Open Access
- 1 July 2002
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 50 (1) , 73-77
Penetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement
Twelve patients undergoing total hip replacement were given 600 mg of linezolid as a 20 min iv infusion along with conventional prophylaxis of 1 g of cefamandole immediately before surgery. Routine total hip arthroplasty was carried out, and at timed intervals during surgery samples of bone, fat, muscle and blood were collected for assay by high-performance liquid chromatography analysis. Samples of the haematoma fluid that formed around the operation site and further blood samples for assay were also collected at timed intervals following the operation. The penetration of linezolid into bone was rapid, with mean concentrations of 9.1 mg/L (95% CI 7.7–10.6 mg/L) achieved at 10 min after the infusion, decreasing to 6.3 mg/L (95% CI 3.9–8.6 mg/L) at 30 min. Correction for the simultaneous blood concentrations gave mean values for bone penetration of 51% at 10 min, 60% at 20 min and 47% at 30 min. Although the penetration of linezolid into fat was also rapid, mean concentrations and degree of penetration were c. 60% of those in bone; at 10 min they were 4.5 mg/L (95% CI 3.0–6.1 mg/L; penetration 27%); at 20 min they were 5.2 mg/L (95% CI 4.0–6.4 mg/L; penetration 37%); and at 30 min, 4.1 mg/L (95% CI 3.3–4.8 mg/L; penetration 31%). For muscle the corresponding values were 10.4 mg/L (95% CI 8.1–12.7 mg/L; penetration 58%) at 10 min, 13.4 mg/L (95% CI 10.2–16.5 mg/L; penetration 94%) at 20 min and 12.0 mg/L (95% CI 9.2–14.8 mg/L; penetration 93%) at 30 min. Mean concentrations of linezolid in the haematoma fluid drained from around the operation site were 8.2 mg/L at 6–8 h and 5.6 mg/L at 10–12 h after the infusion, and 7.0 mg/L at 2–4 h following a second 600 mg infusion given 12 h post-operatively. We conclude that linezolid exhibits rapid penetration into bone, fat and muscle of patients undergoing hip arthroplasty, to achieve levels in excess of its MIC for susceptible organisms (≤4 mg/L); therapeutic concentrations were maintained in the haematoma fluid that surrounds the operation site for >16 h.
- 1 July 2002
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 50 (1) , 73-77
Open AccessPenetration of linezolid into bone, fat, muscle and haematoma of patients undergoing routine hip replacement
Twelve patients undergoing total hip replacement were given 600 mg of linezolid as a 20 min iv infusion along with conventional prophylaxis of 1 g of cefamandole immediately before surgery. Routine total hip arthroplasty was carried out, and at timed intervals during surgery samples of bone, fat, muscle and blood were collected for assay by high-performance liquid chromatography analysis. Samples of the haematoma fluid that formed around the operation site and further blood samples for assay were also collected at timed intervals following the operation. The penetration of linezolid into bone was rapid, with mean concentrations of 9.1 mg/L (95% CI 7.7–10.6 mg/L) achieved at 10 min after the infusion, decreasing to 6.3 mg/L (95% CI 3.9–8.6 mg/L) at 30 min. Correction for the simultaneous blood concentrations gave mean values for bone penetration of 51% at 10 min, 60% at 20 min and 47% at 30 min. Although the penetration of linezolid into fat was also rapid, mean concentrations and degree of penetration were c. 60% of those in bone; at 10 min they were 4.5 mg/L (95% CI 3.0–6.1 mg/L; penetration 27%); at 20 min they were 5.2 mg/L (95% CI 4.0–6.4 mg/L; penetration 37%); and at 30 min, 4.1 mg/L (95% CI 3.3–4.8 mg/L; penetration 31%). For muscle the corresponding values were 10.4 mg/L (95% CI 8.1–12.7 mg/L; penetration 58%) at 10 min, 13.4 mg/L (95% CI 10.2–16.5 mg/L; penetration 94%) at 20 min and 12.0 mg/L (95% CI 9.2–14.8 mg/L; penetration 93%) at 30 min. Mean concentrations of linezolid in the haematoma fluid drained from around the operation site were 8.2 mg/L at 6–8 h and 5.6 mg/L at 10–12 h after the infusion, and 7.0 mg/L at 2–4 h following a second 600 mg infusion given 12 h post-operatively. We conclude that linezolid exhibits rapid penetration into bone, fat and muscle of patients undergoing hip arthroplasty, to achieve levels in excess of its MIC for susceptible organisms (≤4 mg/L); therapeutic concentrations were maintained in the haematoma fluid that surrounds the operation site for >16 h.
- Open Access
- 1 July 2001
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 48 (1) , 154-155
Difficulties in the assay of cefamandole highlight the importance of specific methodologies in pharmacokinetic studies
- 1 July 2001
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 48 (1) , 154-155
Open AccessDifficulties in the assay of cefamandole highlight the importance of specific methodologies in pharmacokinetic studies
- Open Access
- 1 April 2001
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 47 (4) , 483-486
The penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone
Thirteen patients undergoing total hip replacement were given ceftriaxone 1 g and cefamandole 1 g simultaneously, either immediately or 8 h before surgery. For both agents the concentrations seen in the bone and fat during the operation, and for haematoma fluid ≤24 h after the operation, exceeded the MIC for susceptible staphylococci and would be expected to provide adequate prophylaxis. Although ceftriaxone concentrations in bone and fat were significantly higher than those of cefamandole, after correction for the simultaneous blood concentrations, we were unable to detect any differences in the bone or fat penetration of the two agents. We conclude that there is no evidence that cephalosporins with a lower serum protein binding penetrate bone better than ones with higher serum protein binding.
- 1 April 2001
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 47 (4) , 483-486
Open AccessThe penetration of ceftriaxone and cefamandole into bone, fat and haematoma and relevance of serum protein binding to their penetration into bone
Thirteen patients undergoing total hip replacement were given ceftriaxone 1 g and cefamandole 1 g simultaneously, either immediately or 8 h before surgery. For both agents the concentrations seen in the bone and fat during the operation, and for haematoma fluid ≤24 h after the operation, exceeded the MIC for susceptible staphylococci and would be expected to provide adequate prophylaxis. Although ceftriaxone concentrations in bone and fat were significantly higher than those of cefamandole, after correction for the simultaneous blood concentrations, we were unable to detect any differences in the bone or fat penetration of the two agents. We conclude that there is no evidence that cephalosporins with a lower serum protein binding penetrate bone better than ones with higher serum protein binding.
- Open Access
- 1 August 1996
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 38 (2) , 327-328
Once-a-day carbapenem therapy
- 1 August 1996
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 38 (2) , 327-328
Open AccessOnce-a-day carbapenem therapy
- 1 October 1995
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 36 (4) , 745-747
The management of mycobacterial infection— a UK survey
- 1 October 1995
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 36 (4) , 745-747
The management of mycobacterial infection— a UK survey
- 1 September 1994
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 34 (3) , 425-429
Assay of serum teicoplanin concentrations in clinical specimens: a comparison of isocratic high performance liquid chromatography with polarisation fluoroimmunoassay and bioassay
C. M. McMullin, L. O. White, A. P. MacGowan, H. A. Holt, A. M. Lovering, D. S. Reeves; Assay of serum teicoplanin concentrations in clinical specimens: a compar
- 1 September 1994
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 34 (3) , 425-429
Assay of serum teicoplanin concentrations in clinical specimens: a comparison of isocratic high performance liquid chromatography with polarisation fluoroimmunoassay and bioassay
C. M. McMullin, L. O. White, A. P. MacGowan, H. A. Holt, A. M. Lovering, D. S. Reeves; Assay of serum teicoplanin concentrations in clinical specimens: a compar
- 1 March 1993
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 31 (3) , 450
HPLC assay of cefixime in serum and CSF
L. O. WHITE, D. S. REEVES, A. M. LOVERING, A. P. MACGOWAN; HPLC assay of cefixime in serum and CSF, Journal of Antimicrobial Chemotherapy, Volume 31, Issue 3, 1
- 1 March 1993
- Published by Oxford University Press (OUP) in Journal of Antimicrobial Chemotherapy
- Vol. 31 (3) , 450
HPLC assay of cefixime in serum and CSF
L. O. WHITE, D. S. REEVES, A. M. LOVERING, A. P. MACGOWAN; HPLC assay of cefixime in serum and CSF, Journal of Antimicrobial Chemotherapy, Volume 31, Issue 3, 1